P208: Cross-Functional Best Practices to Improve Signal Detection in Special-Case Scenarios
Poster Presenter
Midhun Raj K
Associate Director, Signal Management
IQVIA India
Objectives
Propose a pragmatic, cross-functional framework that strengthens pharmacovigilance signal detection where special-case contexts (e.g., paediatrics, geriatrics, pregnancy, organ impairment, misuse, errors, interactions, quality issues, death) distort causal assessment and delay action
Method
Synthesis of end-to-end practices across PV operations, literature, aggregate/risk management, regulatory/labeling, PQC, statistics, RWE, clinical data, and local/QPPV to define role-specific workflows, scenario-specific data minima, and triage heuristics aligned to lifecycle signal decisions.
Results
Applying a structured, role-clarified model improved completeness, timeliness, and interpretability of evidence for special-case signals. Paediatric and geriatric assessments benefited from age-appropriate denominators, developmental context, and polypharmacy prompts that reduced misclassification and improved trend recognition. In renal and hepatic impairment, standardized capture of eGFR, Child-Pugh scores, exposure windows, and dose adjustments reduced variability and supported clearer causal hypotheses. For pregnancy and lactation, trimester timing, maternal–infant linkage, and breastfeeding details enhanced detection of developmental patterns despite limited data. Ethnicity and genotype fields strengthened stratification where metabolic polymorphisms affect risk. Misuse, abuse, and dependence were better characterized through behavioral cues, unapproved routes, tampering indicators, unjustified dose escalation, and withdrawal descriptions, improving differentiation between toxicity and therapeutic failure. Overdose and underdose data—intent, co-exposures, concentration–effect context, and vulnerability factors—helped distinguish misuse from error and clarified disease progression. Medication errors coded by standard taxonomies isolated preventable harm from product-related issues. Off-label use and lack-of-effect tags preserved analytical validity by preventing conflation of inefficacy with ADRs. Drug–drug interaction detection improved through co-exposure mapping and temporal sequencing. A dedicated product-quality workflow linked batch, device, and stability data to avoid misattributing manufacturing defects to intrinsic safety risks. Aligned review criteria, statistical thresholds, inspection-ready documentation, and harmonized communication practices overall reduced cycle times and strengthened decision fidelity for low-frequency, high-impact safety events.
Conclusion
Special-case scenarios systematically erode the signal-to-noise ratio; without tailored capture and orchestrated collaboration, they bias causality, inflate false signals, and delay risk minimization. A disciplined, scenario-aware operating model—embedded in SOPs, AE intake, literature screening, aggregate reviews, labeling, PQC investigations, and local/QPPV escalation—restores rigor by ensuring the right context is captured once and reused many times. Four pillars underpin impact: (1) scenario-specific minimum data sets (developmental stage; eGFR/Child-Pugh; trimester; allele status; intent/behavioral flags; error taxonomy; batch/lot/device IDs); (2) temporal precision (index dates, exposure windows, latency) to support mechanistic plausibility; (3) stratified analytics (subpopulation models; interaction-aware lenses) to respect heterogeneity of effect; and (4) dual-track handling of product-quality versus pharmacologic harms.
Operationalizing these pillars through training, cross-functional safety huddles, shared dashboards, and predefined decision rules reduces rework, shortens time to signal confirmation/closure, and elevates transparency with regulators via clear traceability from evidence to action. Sponsors adopting this framework can surface true concerns earlier, target risk minimization (label updates, education, controlled distribution), commission focused epidemiology, and deliver more equitable safety evidence for under-represented populations—ultimately enabling faster learning cycles and stronger patient protection across the product lifecycle.
